CALA News and Press, Calithera Biosciences Inc. From 08/06/21

The following slide deck was published by Calithera Biosciences, Inc. in conjunction with this event. For further details see: Calithera Biosciences (CALA) releases investors presentation

Image source: The Motley Fool. Calithera Biosciences, inc (NASDAQ: CALA) Q2 2021 Earnings Call Aug 5, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences, inc (CALA) Q2 2021 Earnings Call Transcrip...

-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021-- SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-int...

Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here co...

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening disease...

Calithera Biosciences Inc. (NASDAQ:CALA) traded today at a new 52-week low of $1.78. This new low was reached on approximately average trading volume as 760,000 shares traded hands, while the average 30-day volume is approximately 1 million shares. There is potential upside of 14.2% for ...

Shares of Calithera Biosciences Inc. (NASDAQ:CALA) traded today at $1.86, breaking its 52-week low. This new low was reached on approximately average trading volume as 760,000 shares traded hands, while the average 30-day volume is approximately 1.1 million shares. Calithera Biosciences ...

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today shared fi...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced ...